Medicare and its beneficiaries are paying significantly more for Stelara, Johnson & Johnson’s (NYSE:JNJ) popular biologic drug used to treat autoimmune diseases when obtained through pharmacies rather ...
Patients may now switch between Otulfi and Stelara without requiring a prescription change from a health care provider. The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab-aauz ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback